Drug Discovery

Overview

We have developed unique cell types that can be used for accelerating the drug discovery process, for organ or tissue printing, for high throughput and high content screening, for toxicity and efficacy testing, and for human disease modeling.

Our high-quality specialized human cells are derived from human (non-embryo) induced pluripotent stem cells (iPSCs).

We have developed novel protocols for making midbrain dopaminergic (mDA) neurons, forebrain parvalbumin-expressing interneurons, and oligodendrocytes of the human central nervous system (CNS).

These specialized human cells can be used for drug discovery in developing treatments for Parkinson’s Disease, Alzheimer’s Disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), leukodystrophies, cerebral palsy, Pelizaeus-Merzbacher Disease, neuropsychiatric disorders, schizophrenia, autism, and intellectual disabilities.

In addition, we have developed endothelial cells as well as  functionally mature human pancreatic islet cells (beta cells). These cells are critical for organ and tissue printing and disease modeling as well as for accelerating the drug discovery process at pharma and biotech companies working on diabetes (Type 1 or 2) related therapeutics.